Relapsed Multiple Myeloma Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Relapsed Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple Myeloma
Alfred Chung, MD32 enrolled1 locationNCT06348108
Recruiting
Phase 2

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Refractory Multiple MyelomaRelapsed Multiple Myeloma
Benjamin T Diamond, MD30 enrolled1 locationNCT05896228
Recruiting
Early Phase 1

Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

Multiple MyleomaRefractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)30 enrolled1 locationNCT06663046
Recruiting
Phase 4

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

Multiple Myeloma, RefractoryRelapsed Multiple Myeloma
CHU de Quebec-Universite Laval80 enrolled1 locationNCT07094048
Recruiting
Phase 1

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple MyelomaRelapsed Multiple Myeloma
Opna Bio LLC130 enrolled10 locationsNCT06433947
Recruiting
Phase 3

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

Refractory or Relapsed Multiple Myeloma
Celltrion486 enrolled1 locationNCT06952478
Recruiting
Phase 1Phase 2

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+4 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685
Recruiting
Phase 1Phase 2

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

Relapsed Multiple Myeloma
PETHEMA Foundation60 enrolled15 locationsNCT05060627